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Abstract
Objectives The objectives were to measure uptake of and
factors associated with human papillomavirus (HPV) vac-
cination initiation and to determine whether HPV vacci-
nation reduced the uptake of cervical cancer screening.
Methods We conducted a cross-sectional survey in a ran-
dom sample of Swiss women aged 18–49 years in 2014
(N = 3588).
Results Vaccination initiation was 69.3% and full cover-
age (three doses) 54.1% for 18–20-year olds, respectively,
42.4% and 33.9% for 21–24-year olds. Women with C 10
lifetime sexual partners were less likely to have received
any HPV vaccination than women with B 2 partners
(18–20 years OR 0.2, 21–24 years OR 0.5). Amongst 1000
unvaccinated women (18–24 years), reasons for not having
initiated vaccination were lack of information (22.5%) and
fear of vaccine side effects (18.1%). Vaccination status was
not associated with adherence to cervical cancer screening
recommendations (OR 1.3). 95.4% of all vaccinated par-
ticipants knew about the continued need for screening.
Conclusions Our data suggest that HPV vaccination is not
associated with reduced uptake of cervical cancer
screening. This study provides information that can be used
to improve HPV vaccination uptake in Switzerland.
Keywords HPV vaccination  Cervical cancer screening 
Determinants  Vaccine hesitancy  Sexual behavior
Introduction
The aim of human papillomavirus (HPV) vaccination
programs is to reduce the incidence of cervical cancer and
other HPV-associated cancers (Barr and Sings 2008).
Several European countries, including the United King-
dom, Portugal and Denmark have achieved targets of 80%
for completed HPV vaccination (ECDC 2012; Public
Health England 2015; Statens Serum Institute 2013). In
Switzerland, HPV vaccination was included in the National
Vaccination Plan in 2007 for 11- to 26-year-old women
(Bundesamt fu¨r Gesundheit and EKIF 2008). The recom-
mended age for primary HPV vaccination in Switzerland is
11–14 years. The majority of cantons provide the vacci-
nation to this age group through school health services. The
national target until 2012 was 80% full coverage for
11–14-year olds and 50% for catch-up vaccination in
15–19-year olds. The Swiss National Vaccination Cover-
age Survey routinely collects HPV vaccination coverage in
16-year olds (Bundesamt fu¨r Gesundheit 2008). Since
2008, each of the 26 cantons (states) in Switzerland has
been responsible for organizing its own HPV vaccination
program. The cost of HPV vaccination is fully covered by
health insurance for vaccinations administered within
public health vaccination programs (Bundesamt fu¨r
Gesundheit 2010a, b). Health insurance also covers
Papanicolaou (Pap) screening, the other main measure to
control cervical cancer. The Swiss Gynecological Society
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recommends Pap screening from age 21 or from the start of
sexual activity every 2 years. In 30- to 70-year-old women,
screening should be performed every 3 years assuming that
the last three screening test results were normal. Thereafter,
screening is only continued in case of continued sexual
activity or previous abnormal screening results
(Gyne´cologie Suisse, Kommission Qualita¨tssicherung
2012).
Concerns have been raised that HPV-vaccinated women
might forgo cervical cancer screening, owing to a false
sense of security (ECDC 2012), or that women who are not
vaccinated against HPV might also be less likely to attend
cancer screening. The objectives of this study were: to
determine HPV vaccination initiation and full coverage and
the factors associated with initiation of vaccination in
Switzerland; to determine the reasons for not being vac-
cinated against HPV; to see if women know about the need
for cervical cancer screening after HPV vaccination; and to
determine whether HPV vaccination affects adherence to
cervical cancer screening recommendations.
Methods
We designed a nationally representative cross-sectional
questionnaire survey. A professional telephone survey
company conducted the recruitment and data collection.
The questionnaire included questions on participants’ self-
reported HPV vaccination status. Women were asked
whether they had used their vaccination record to complete
this question or not. The interview team did not have
access to the hard copies of the vaccination records.
Additional questions included reasons for receiving or not
receiving HPV vaccination; sexual behavior; cervical
cancer screening behavior and outcome; and lifetime
occurrence of genital warts. All questions were multiple
choice or open questions. Some questions included a cat-
egory ‘‘other’’ which could be completed as free text. Our
questionnaire was available in French, German and Italian
either as telephone survey, as self-administered paper or as
online questionnaire. The telephone interview took about
11 min, the online version nine minutes to complete. We
piloted the sampling procedure and questionnaire with 227
completed interviews between November 18 and Decem-
ber 4, 2013. Invitation letters for the main survey were sent
from January 24, 2014 onwards. The main survey took
place between February 29 and May 26, 2014.
Participants and recruitment
Inclusion criteria for participation in the study were: female
sex; aged 18–49 years; address within Switzerland recor-
ded in a commercial directory; and ability to answer
questions in German, French or Italian. We used a com-
mercial household directory, which covers about 95% of all
Swiss private households, to select households with 18- to
49-year-old women. We used stratified random sampling
based on two age classes, 18–24 and 25–49 years, three
language regions and municipality size. We sent each
selected household a letter giving background information.
The telephone interview first screened for eligibility by sex
and age. For households without a registered telephone
number, the information letter asked a woman aged
18–49 years to respond and, if there was more than one
eligible woman, we asked the woman who most recently
had her birthday to participate (Hu¨fken 2003). We offered
an incentive of CHF 10 for either a self-completed mailed
or online response. If the questionnaire was not completed
within 2 weeks, a reminder was sent.
We aimed to interview 2250 women who had been
eligible for primary or catch-up vaccination after cantonal
vaccination programs had started. At the time of the survey
in 2014, girls aged 11–14 years in 2008 were aged 17–20
and those aged 15–18 years were aged 21–24. We exclu-
ded 17-year olds because they were too young to give
consent to participate. To obtain comparable data about
cervical cancer screening behavior, we included older
women aged 25–49 years; target sample size for this age
class was 1125.
Statistical analyses
We applied three sampling weights to generate estimates
that were nationally representative. First, inverse proba-
bilities for selection of households and women within each
household, according to language region, age of household
members and existence of a telephone number; second, a
weight to account for the 2:1 ratio of younger to older
women for each language region and annual age classes;
third, a constant factor to correct for the actual sample size.
To calculate response rate, we divided the number of
completed interviews by the estimated number of eligible
households, based on guidelines from the Council of
American Survey Research Organizations (CASRO 1982).
We present descriptive statistics with 95% confidence
intervals (CI); numbers are the unweighted totals and
percentages are those after applying the survey weights. Of
the 3622 completed interviews we excluded 34 with
impossible values for age at vaccination and vaccine type.
We did not impute any missing values. We used weighted
logistic regression to investigate factors associated with
HPV vaccination and cervical cancer screening behaviors.
We stratified analyses for vaccination initiation by age
class 18–20 years and 21–24 years (and report results for
completed vaccination in Supplementary Table 5). In the
models about adherence to cervical cancer screening
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recommendations by the Swiss Gynecological Society, we
focused on sexually active women aged 20–49 years only;
adherence to guidelines was considered to be present if 20-
to 29-year-old women had a Pap test every 2 years or more
often; 30- to 49-year-old women every 3 years or more
often (Gyne´cologie Suisse 2012). For both outcomes,
vaccination and screening, we examined the same inde-
pendent categorical variables: language region (German,
French, Italian); migratory background (yes, no); education
(primary and lower secondary, upper secondary and post-
secondary non-tertiary, undergraduate and post-graduate);
household income (CHF\ 5000, 5000–8999, C 9000);
smoking (never, current and stopped), age at first sexual
intercourse (\ 18 years, C 18 years), number of lifetime
sexual partners (0–2, 3–9, C 10) and use of hormonal
contraception (no, yes, not yet sexually experienced). In
addition, we included initiation of vaccination (yes, no) as
an independent variable in the screening model and initi-
ation of cervical cancer screening (yes, no) in the vacci-
nation model. We report results for univariable and
multivariable models as odds ratios (OR) with 95% CI. We
performed all the analyses with the survey function of
Stata/SE 14.0 for Windows (StatCorp LP, College Station,
TX, USA).
Results
We published a German and French language summary of
the methods and descriptive results in our surveillance
bulletin in 2015 (Bundesamt fu¨r Gesundheit 2015a, b).
Response rate, demographic characteristics
and sexual behavior
We randomly selected 7137 households, 5007 with and 2130
without registered telephone numbers. We obtained 3622
completed interviews, 2446 of these were in the age group
18–24 years and 1176 in the age group 25–49 years (Fig. 1).
The estimated overall response rate for eligible women was
66.2%; 76.3% for those with registered telephone numbers
and 57.2% for those without telephone numbers. We ana-
lyzed 3588 interviews, 2414 with 18–24-year olds and 1174
with 25–49-year olds. We excluded 34 interviews from
analysis because vaccination dates were implausible, e.g.,
vaccination date before date of approval of the HPV vaccines
in Switzerland or incorrect brand name of vaccine provided.
The median age was 21 years in the 18–24-year olds and
40 years in the 25–49-year olds; median number of lifetime
sexual partners was 2 for the former and 4 for the latter age
group. We provide further demographic characteristics and
sexual behavior reported by the participating women in
Supplementary Tables 1 and 2.
HPV vaccination coverage and reasons for not being
vaccinated
Table 1 provides information about HPV vaccination.
Amongst 18- to 20-year-old women in 2014 (aged
12–14 years in 2008), 69.3% (95% CI 61.1–76.5%) had
initiated HPV vaccination (C 1 dose) and 54.1% (95% CI
45.4–62.6%) had received three doses. Of the 21–24-year
olds (aged 15–18 years in 2008), 42.4% (95% CI
36.8–48.2%) had initiated and 33.9% (95% CI
28.7–39.4%) had completed HPV vaccination. Vaccination
coverage was highest in women aged 18 years in 2014
(74.0%, 95% CI 58.9–85.0% for initiation and 63.5%, 95%
CI 47.9–76.7% for completion) (Fig. 2). 97.2% (95% CI
94.7–98.5%) of vaccinations done at the recommended age
of 11–14 years were administered before first sexual
intercourse. In the age group 25–49 years, 2.5% (95% CI
1.4–4.5%) had initiated and 1.6% (95% CI 0.8–3.3%)
completed vaccination. In the group of women aged
18–24 years, 39.3% used their vaccination records to
confirm vaccination details and in the group aged
25–49 years, 14.6% checked their vaccination records.
In Table 2, we present the reasons provided by the 1000
women aged 18–24 years with zero HPV vaccine doses for
not having initiated HPV vaccination (participants could
give more than one reason). The two major reasons given
by 18–20-year olds (N = 321) were fear of vaccine side
effects (30.3%, 95% CI 16.8–48.3%) and being opposed to
HPV vaccination (20.7%, 95% CI 10.5–36.9%). In the age
group 21–24 years (N = 679), the two major reasons were
lack of information (24.7%, 95% CI 18.3–32.3%) and
having had already sexual partners (21.2%, 95% CI
14.4–30.0%).
Factors associated with HPV vaccination
Table 3 shows factors associated with initiation of HPV
vaccination. Women who reported C 10 lifetime partners
in 2014 were less often vaccinated than women who
reported 0–2 partners (18–20 years OR 0.2, 95% CI
0.0–0.5; 21–24 years OR 0.5, 95% CI 0.3–1.0). Women in
the French-speaking region were more likely to initiate
vaccination than those in the German-speaking region
(18–20 years OR 2.5, 95% CI 1.3–4.8; 21–24 years OR
3.1, 95% CI 2.1–4.6). In 21–24-year olds, initiation of
catch-up vaccination was also more frequent in the Italian-
speaking than in the German-speaking region (OR 2.5,
95% CI 1.1–5.7). In this age group, women with the
highest level of household income had an OR of 2.4 (95%
CI 1.5–3.8) for having started catch-up vaccination com-
pared with women with the lowest income. Women aged
21–24 years using hormonal contraception were more
likely to have initiated vaccination than those not using
Human papillomavirus vaccine uptake in adolescence and adherence to cervical cancer…
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hormonal contraception (OR 1.5, 95% CI 1.0–2.3). In both
age groups, we observed no association between cervical
cancer screening and initiation of vaccination
(18–20 years, OR 1.3, 95% CI 0.6–2.7; 21–24 years OR
1.1, 95% CI 0.6–1.9). Results of logistic regression anal-
ysis for factors associated with completed vaccination are
given in Supplementary Table 5.
Factors associated with cervical cancer screening,
screening behavior and knowledge about screening
recommendations after HPV vaccination
When asked about the necessity for cervical cancer
screening after HPV vaccination, 75.2% (95% CI
67.6–81.4%) of all vaccinated women (N = 1385) stated
that cervical cancer screening should be continued at the
same frequency; 20.3% (95% CI 14.2–28.1%) thought that
screening is still needed after HPV vaccination but less
often; 0.8% (95% CI 0.5–1.4%) considered screening
unnecessary after HPV vaccination; and 3.8% (95% CI
2.6–5.5%) did not know. Among unvaccinated women
(N = 2111), the values were 56.2% (95% CI 52.1–60.0%),
30.2% (95% CI 27.3–34.5%), 1.5% (95% CI 0.8–2.9%)
and 12.0% (95% CI 9.4–14.4%), respectively.
In the age group 18–24 years (N = 2345), 71.7% had
had at least one Pap test; the value was 72.7% (95% CI
65.2–79.1) for women not having initiated HPV vaccina-
tion and 69.9% (95% CI 62.7–76.2%) for vaccinated
women. 98.1% of women aged 25–49 years (N = 1141)
had had at least one Pap test (Supplementary Table 3).
Amongst women having initiated Pap testing, 77.7% (95%
CI 73.2–81.7%) of 18–24-year olds and 65.0% (95% CI
60.8–68.9%) of 25–49-year olds had Pap tests annually,
which is more often than recommended by the expert
guidelines.
In multivariable analysis, which focused on sexually
active women aged 20–49 years, we found that having
been vaccinated against HPV was not associated with
randomly selected households based 
on an address directory with sex and 
age attributes  N=7137
with telephone 
number N=5007
number invalid (out of 
service, fax) N=309
number valid 
N=4698
no contact established (no 
answer, line occupied 
answering machine) N=462
contact 
established 
N=4236
communication not possible 
(language barrier) N=55
communication 
possible N=4181
refusal to 
partcipate 
N=890
willing to participate
N=3291
no woman within 
target age group 
N=420
woman within 
target age group 
N=2871
interview scheduled 
outside survey 
period N=101
interview not 
completed N=84
interview 
completed 
N=2686
CATI* N=2580
CATI & paper 
N=35
CATI & online 
N=71
without 
telephone 
number N=2130
address invalid 
(mail returned) 
N=254
address valid 
N=1876
no response 
N=901 response N=975
refusal to 
participate N=8
no woman within 
target age group 
N=28
woman within 
target age group 
N=947
interview not 
completed N=3
interview completed 
N=936
paper N=797
online N=139
Fig. 1 Enrollment process of the participants in the Swiss human papillomavirus survey (Switzerland 2014). Asterisk indicates that CATI is an
abbreviation for computer assisted telephone interview
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adherence to cervical cancer screening recommendations
(OR 1.3, 95% CI 0.8–2.1). Besides age, household income
and use of hormonal contraception affected adherence to
cervical cancer screening recommendations. Women with
high income had an OR of 2.3 (95% CI 1.2–4.6) to adhere
to screening recommendations compared with women
with low income. Women using hormonal contraception
were more likely to adhere to screening recommendations
than those not using hormonal contraception (OR 3.5,
95% CI 1.8–6.6). We provide complete results of multi-
variable analysis of cervical cancer screening and addi-
tional information on mean age at first Pap test, timing of
first Pap test in relation to first sexual intercourse, results
of cervical cancer screening and frequency of operations
at the cervix in Supplementary Tables 3 and 4. Of the
18–24-year olds (N = 725) who had never had a Pap test,
only 0.5% (95% CI 0.1–2.1%) reported being vaccinated
against HPV as a reason for not having initiated Pap
testing.
Discussion
Our survey shows that reported levels of completed HPV
vaccination amongst women aged 18–24 years in 2014
were below the target of 80%. Regional differences in
initiation of vaccination were present and women who
reported higher numbers of sexual partners when they were
interviewed in 2014 were less likely to have initiated HPV
vaccination. The main reasons that women gave for not
being vaccinated were fear of vaccine side effects and lack
of information. HPV vaccination initiation was not asso-
ciated with a reduction in the subsequent uptake of cervical
cancer screening.
Strengths and limitations
Major strengths of this study are its national coverage and
the wide range of topics concerning HPV vaccination,
including factors associated with vaccination and reasons
for lack of vaccination, obtained from the same study
population. In the absence of a vaccine registry, surveys
offer a way to investigate HPV vaccine uptake and cervical
Table 1 Human papillomavirus vaccination status reported by
women aged 18–24 years (Swiss human papillomavirus survey,
Switzerland 2014)
N Percentage,
median
95% CI or
SD (%)
Number of HPV vaccine doses 2363
0 dose 46.6% 41.6–51.6
1 dose 5.4% 3.6–8.0
2 doses 4.7% 3.3–6.6
3 doses 41.3% 36.4–46.3
Vaccinated, number of doses
unknown
2.2% 1.6–2.9
HPV vaccination initiated, by
language region
2363
French 68.1% 60.6–74.8
German 47.4% 41.1–53.9
Italian 63.3% 51.6–73.6
Age at first HPV vaccine dose 1243
11–14 years 39.8% 32.7–47.5
15–19 years 54.4% 47.2–61.4
C 20 years 5.8% 4.1–8.1
Median 15 years
Vaccine type(s) received 826
Quadrivalent 95.0% 81.7–97.0
Bivalent 3.5% 2.1–5.9
Quadrivalent and bivalent 1.5% 0.4–4.9
Timing of vaccination at age
11–14 years in relation to first
sexual intercourse
470
Before first sexual intercourse 97.2% 94.7–98.5
Same year 2.3% 1.2–4.3
After first sexual intercourse 0.5% 0.1–3.5
Timing of catch-up vaccination
at age 15–19 years in relation
to first sexual intercourse
716
Before first sexual intercourse 49.7% 42.4–56.9
Same year 19.1% 14.3–25.1
After first sexual intercourse 31.2% 25.6–37.4
CI confidence interval; SD standard deviation. All estimates are
weighted. The denominator N (unweighted) varies across variables
because of item non-response and questions restricted to subgroups
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and full coverage in 18–24-year olds (n = 2363) (Swiss human
papillomavirus survey, Switzerland 2014)
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cancer screening in detail. The survey also has several
limitations. First, the data are self-reported and vaccination
status was confirmed by written records for only a minority
of women. Reported vaccination coverage was, however,
in line with the findings of routine Swiss vaccination
coverage surveys (SNVCS), which record national cover-
age by age 16 years of 51% for completion (three doses)
during the survey period 2011–2013 (Bundesamt fu¨r
Gesundheit 2015a, b). Second, the sampling frame did not
reach all eligible women with the same probability. The
response of 76% was adequate for women interviewed by
telephone but lower for women without registered tele-
phone number (57%). We found that women aged
18–24 years with a registered telephone number who
completed at least part of the interview by CATI reported
higher vaccination coverage than those without registered
telephone number doing the interview either online or on
paper. But based on our design, we cannot say if this
observed difference is due to the interview mode or to other
factors associated with having a registered telephone
number. To attenuate some of the potential biases intro-
duced by the sampling procedure and study design, we
used a complex weighting procedure. Third, questions
about socioeconomic factors were asked up to 8 years after
vaccination. This delay could bias results if socioeconomic
position had changed for a large proportion of women.
Finally, women of migrant background were
underrepresented.
Implications for vaccination programs
HPV vaccination uptake in Switzerland, 6 years after the
programs started in 2008, did not reach the targets that had
been set for either primary or catch-up vaccination. Many
other European countries (ECDC 2012) and the USA
(Williams et al. 2016) have also had lower coverage than
expected. Our survey also shows the lower uptake of HPV
vaccination by women in the German than French or Italian
language regions in Switzerland. An evaluation of HPV
vaccination programs in Switzerland showed higher vac-
cination coverage levels in cantons in which school health
services are involved in the delivery of vaccination for the
main age group of 11- to 14-year-old children. In cantons
in which school-based delivery is available, coverage was
around 60%, compared with around 40% in cantons with-
out during the survey period 2011–2013 of the SNVCS
(Spaar and Masserey 2015); such programs are more
common in French than in German-speaking cantons
(Bundesamt fu¨r Gesundheit 2010a, b; Jeannot et al. 2012).
An international systematic review of HPV vaccine uptake
in adolescents confirms the higher coverage achieved by
school-based vaccination programs (Kessels et al. 2012). A
mathematical modeling study from the USA, where
heterogeneity in vaccination coverage between states
(20–57%) is similar to that in Switzerland suggests that
expansion of coverage would have the greatest health
impact in states with the lowest coverage (Durham et al.
Table 2 Reasons given by Swiss women aged 18–24 years for not having initiated human papillomavirus vaccination (multiple answers
permitted) (Swiss human papillomavirus survey, Switzerland 2014)
18–20 yearsa 21–24 yearsb 18–24 years (combined)
% 95% CI % 95% CI % 95% CI
Not (sufficiently) informed about HPV vaccination 16.9 8.9–29.7 24.7 18.3–32.3 22.5 17.2–28.9
Fear of vaccine side effects 30.3 16.8–48.3 13.5 8.8–20.2 18.1 12.5–25.5
Had already one or more sexual partners 3.6 1.7–7.4 21.2 14.4–30.0 16.4 11.3–23.2
Opposed to vaccination in general 20.7 10.5–36.9 11.5 7.0–18.3 14.0 9.3–20.5
HPV vaccination is for younger girls/too oldc 0.6 0.2–2.1 15.9 9.7–25.1 11.7 7.1–18.8
No time or forgotten 11.6 7.2–18.1 10.1 7.4–13.6 10.5 8.1–13.5
Physician advised against vaccination 5.4 2.9–9.8 8.0 5.5–11.6 7.3 5.3–10.0
Friends/family advised against vaccination 12.0 6.1–22.3 3.4 2.2–5.3 5.8 3.7–8.8
Thinks vaccine does not work 4.9 2.7–8.6 3.1 1.9–4.9 3.6 2.5–5.1
Would rather rely on cervical cancer screening than
vaccination
2.1 7.9–5.5 3.4 2.1–5.5 3.1 2.0–4.7
Other reasons 14.9 9.8–22.2 13.8 10.5–18.0 14.1 11.2–17.6
Refusal or do not know 4.0 2.2–7.1 3.7 2.3–5.8 3.8 2.6–5.4
All estimates are weighted. CI confidence interval
aTarget group for primary vaccination in 2008 (aged 12–14 years), N = 321
bTarget group for catch-up vaccination in 2008 (aged 15–18 years), N = 679
cBased on their year of birth, all women had been within the target age range for HPV vaccination in 2008
M. N. Wymann et al.
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2016). Encouraging school health service involvement in
all cantons, but particularly in those with the lowest vac-
cination coverage, could improve vaccination coverage
nationally.
A recent meta-analysis did not find strong evidence for
differences in HPV vaccination initiation by parental edu-
cation or income (Fisher et al. 2013). In our survey, we
found no influence of socioeconomic factors in the target
group for vaccinations at 11–14 years. However, in the
target group for catch-up vaccinations, women with lower
income were less likely to be either vaccinated or screened,
constituting a risk group for development of cervical
cancer.
Understanding reasons for not being vaccinated at the
individual level can indicate ways in which vaccination
coverage could be improved and disparities reduced. Two
of the most commonly cited reasons for not being vacci-
nated were lack of information and fear of vaccine side
effects. These are factors that could be dealt with by
improvements in public and school-based information
campaigns. One in five 18–20-year olds said that they were
not vaccinated against HPV because of opposition to vac-
cination in general or HPV vaccination in particular, pre-
sumably reflecting their parents’ decision. Dialog-based
interventions might help to overcome part of this vaccine
hesitancy (Jarrett et al. 2015).
HPV vaccination and sexual behavior
Our survey shows the importance of maximizing HPV
vaccination uptake before sexual debut because there are
no good predictors of future risky sexual behavior. Women
in our survey who had the highest numbers of lifetime
sexual partners (C 10) at the time they were interviewed
were those who were least likely to have received HPV
vaccination when they were younger (47%). A survey in
Australia found a similar association; women aged
20–29 years with 10 or more lifetime partners were less
likely than those with fewer than two partners to have
received any HPV vaccine (OR 0.54, 0.31–0.96) (Canfell
et al. 2015). In Australia, however, 75% of women with the
highest number of sexual partners had initiated vaccination.
The observed association between HPV vaccination and
lower numbers of future sexual partners should further
allay fears that HPV vaccination increases unsafe sexual
behavior and confirms that HPV vaccination in girls does
not lead to increases in adverse outcomes of sexual activity
(Bednarczyk et al. 2012).
Role of gynecologists in HPV vaccination
For women beyond school age in Switzerland, gynecolo-
gists are the main contact persons for the provision of HPVT
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vaccination: Many young women go to a gynecologist for
prescriptions for hormonal contraception, which provides
opportunities for catch-up HPV vaccination (Canfell et al.
2015). Overall, gynecologists had delivered a quarter of the
catch-up vaccinations in Switzerland (Bundesamt fu¨r
Gesundheit 2015a, b). They are well placed to publicize the
recommendation for HPV vaccination irrespective of sex-
ual experience for women below 20 years and to fill the
information gaps and alleviate doubts about vaccine safety.
Visits to a gynecologist were associated with an increased
uptake of HPV vaccination in a population-based survey in
Germany (Poethko-Mu¨ller et al. 2014).
HPV vaccination and cervical cancer screening
HPV vaccination was not associated with reduced adher-
ence to cervical cancer screening recommendations
amongst Swiss women. The women in our survey also had
high levels of knowledge about the continued need for
cervical cancer screening after HPV vaccination, confirm-
ing findings amongst US women (Anhang Price et al.
2011). Our survey found that cervical cancer screening
practices could be improved in Switzerland. A majority of
women reported that they had Pap testing more often than
recommended, i.e., annually instead of every 2 or 3 years,
half had their first Pap test before the recommended age of
20 years; and nearly one-third had a Pap test before their
first sexual intercourse, which is clearly against recom-
mendations and does not reduce cervical cancer cases
(Moscicki 2010). New technologies for HPV vaccination
and cervical cancer screening, including two-dose vacci-
nation schedules, the introduction of a nonavalent HPV
vaccine and HPV testing of cytology specimens should be
coordinated to maximize cervical cancer prevention efforts
for all women.
Conclusions
Cross-sectional studies that provide detailed data about
HPV vaccination, sexual behavior and cervical cancer
screening behavior in nationally representative samples of
the population are important sources of information for
improving vaccination programs and for modeling studies
of the predicted impact of HPV vaccination. This study
demonstrates a large potential for improving HPV vaccine
uptake in Switzerland. It will be important to tackle
regional disparities in HPV vaccination coverage as well as
information gaps and doubts about vaccine safety. Our data
suggest that HPV vaccination is not associated with a
reduced uptake of cervical cancer screening. This study
provides information that can be used to improve HPV
vaccination uptake in Switzerland.
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